the cancer and leukemia group b ( calgb ) utilized a randomized phase ii trial design to evaluate two cisplatin-based combinations , cisplatin-cytarabine ( ara-c ) and cisplatin-vinblastine , in 151 patients with advanced non-small cell lung cancer .
C0008838
cisplatin
C0278635
cisplatin-cytarabine